News: Optiscan has growth pathway with second generation imaging platform

Optiscan (ASX:OIL) could be on the path for growth with its entry into the final stages of development of its second generation neurosurgery imaging platform for Carl Zeiss, the world leader in visualisation systems for neurosurgery.

Discussions are continuing with the German manufacturer in relation to improving their commercial arrangements, which are likely to conclude in the September 2015 quarter.

Investors have an opportunity to Optiscan is currently raising about $690,000 through a fully underwritten 1 for 15 pro rata rights issue priced at $0.05.

This adds to the $500,000 in debt funding it has secured, providing the company with increased working capital to support product development and regulatory preparations and consequent business growth.

The company’s second generation animal imaging system, CellLIVE, is expected to generate its first sales in the September quarter while its lead clinical product using the latest second generation imaging platform is its neurosurgery imaging system.

This system is in the final stages of development with activities now focussed on regulatory submission.

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.